1. Home
  2. ZKH vs CMPX Comparison

ZKH vs CMPX Comparison

Compare ZKH & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZKH Group Limited

ZKH

ZKH Group Limited

N/A

Current Price

$2.92

Market Cap

465.1M

Sector

N/A

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.38

Market Cap

408.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZKH
CMPX
Founded
1998
2014
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
465.1M
408.8M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ZKH
CMPX
Price
$2.92
$2.38
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.57
AVG Volume (30 Days)
111.6K
3.3M
Earning Date
05-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$9.02
N/A
Revenue Next Year
$10.41
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$1.61
52 Week High
$3.90
$6.88

Technical Indicators

Market Signals
Indicator
ZKH
CMPX
Relative Strength Index (RSI) 53.65 59.42
Support Level $2.88 $1.68
Resistance Level $2.98 $2.47
Average True Range (ATR) 0.10 0.14
MACD -0.01 0.04
Stochastic Oscillator 76.81 76.87

Price Performance

Historical Comparison
ZKH
CMPX

About ZKH ZKH Group Limited

ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. Majority of the revenues are derived from the PRC.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: